Cargando…

A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a (14)C‐Microtracer Approach

Zimlovisertib (PF‐06650833) is a selective, reversible inhibitor of interleukin‐1 receptor‐associated kinase 4 (IRAK4) with anti‐inflammatory effects. This phase 1, open‐label, fixed‐sequence, two‐period, single‐dose study aimed to evaluate the mass balance and excretion rate of zimlovisertib in hea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Ravi Shankar P., Dowty, Martin E., Salganik, Mikhail, Brodfuehrer, Joanne I., Walker, Gregory S., Sharma, Raman, Beebe, Jean S., Danto, Spencer I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322294/ https://www.ncbi.nlm.nih.gov/pubmed/35506501 http://dx.doi.org/10.1002/cpdd.1109

Ejemplares similares

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
por: Raje, Sangeeta, et al.
Publicado: (2018)

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach
por: Wang, Xiaomin, et al.
Publicado: (2019)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study
por: van Groen, Bianca D., et al.
Publicado: (2020)

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021)

Proof of Concept: First Pediatric [(14)C]microtracer Study to Create Metabolite Profiles of Midazolam
por: van Groen, Bianca D., et al.
Publicado: (2020)

An Investigation of the Metabolism and Excretion of KD101 and Its Interindividual Differences: A Microtracing Mass Balance Study in Humans
por: Kim, Anhye, et al.
Publicado: (2020)

Opportunities in low-level radiocarbon microtracing: applications and new technology
por: Vuong, Le Thuy, et al.
Publicado: (2015)

Pharmacokinetics, Excretion, and Mass Balance of [(14)C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
por: Ambery, Claire, et al.
Publicado: (2018)

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
por: Ma, Shuguang, et al.
Publicado: (2019)

The stable isotope method for determining absolute bioavailability
por: Atkinson, Arthur J.
Publicado: (2017)

An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat
por: Prakash, Chandra, et al.
Publicado: (2023)

Pharmacokinetics, Biotransformation, and Excretion of [(14)C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis
por: Subramanian, Raju, et al.
Publicado: (2016)

Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia
por: Hu, Jun-Hao, et al.
Publicado: (2019)

Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid
por: Flanagan, Shawn, et al.
Publicado: (2014)

Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers
por: Teng, Renli, et al.
Publicado: (2014)

The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats(®)) in Cats
por: Kong, Jingyuan, et al.
Publicado: (2023)

Absolute oral bioavailability and disposition kinetics of puerarin in female rats
por: Anukunwithaya, Tosapol, et al.
Publicado: (2018)

Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals
por: Kvitne, Kine Eide, et al.
Publicado: (2023)

Permeability Enhancers Dramatically Increase Zanamivir Absolute Bioavailability in Rats: Implications for an Orally Bioavailable Influenza Treatment
por: Holmes, Eric H., et al.
Publicado: (2013)

Absolute Oral Bioavailability of Creatine Monohydrate in Rats: Debunking a Myth
por: Alraddadi, Eman A., et al.
Publicado: (2018)

Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a (26)Al Microtracer Approach
por: de Ligt, Rianne, et al.
Publicado: (2018)

Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero‐Test bile string
por: Tai, Guoying, et al.
Publicado: (2023)

Determination of Tangeretin in Rat Plasma: Assessment of Its Clearance and Absolute Oral Bioavailability
por: Elhennawy, Mai Gamal, et al.
Publicado: (2017)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants
por: Ucpinar, Sibel, et al.
Publicado: (2023)

Effect of anions or foods on absolute bioavailability of calcium from calcium salts in mice by pharmacokinetics
por: Ueda, Yukari, et al.
Publicado: (2013)

Pharmacokinetics, absolute bioavailability and tolerability of ketamine after intranasal administration to dexmedetomidine sedated dogs
por: Vlerick, Lise, et al.
Publicado: (2020)

Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers
por: Johne, Andreas, et al.
Publicado: (2020)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
por: Danto, Spencer I., et al.
Publicado: (2019)

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2021)

Pharmacokinetics, absorption, and excretion of radiolabeled revexepride: a Phase I clinical trial using a microtracer and accelerator mass spectrometry-based approach
por: Flach, Stephen, et al.
Publicado: (2016)

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
por: Shaik, Naveed, et al.
Publicado: (2019)

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2022)

Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers
por: Kotani, Naoki, et al.
Publicado: (2018)

New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats
por: AbuElfadl, Aya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s1nafrcfhg60q9gg2eolq2r6c1